Cargando…

Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

BACKGROUND: Widespread implementation of immune checkpoint inhibitors (ICI) and targeted therapies for metastatic melanoma has led to a decline in melanoma-related mortality but increased healthcare costs. We aimed to determine how healthcare utilization varied by systemic, non-adjuvant melanoma tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Mollie F, Betancourt, Nicolas J, Pineda, Alain, Maloney, Nolan J, Nguyen, Kevin A, Reddy, Sunil A, Hall, Evan T, Swetter, Susan M, Zaba, Lisa C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Melanoma and Cutaneous Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020812/ https://www.ncbi.nlm.nih.gov/pubmed/36302223 http://dx.doi.org/10.1093/oncolo/oyac219

Ejemplares similares

Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019)

Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors
por: Grad, Robert N, et al.
Publicado: (2023)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Management of Acral and Mucosal Melanoma: Medical Oncology Perspective
por: Jung, Seungyeon, et al.
Publicado: (2022)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021)

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy
por: Atkinson, Thomas M, et al.
Publicado: (2023)

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis
por: Yarza, Ramon, et al.
Publicado: (2023)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
por: Di Guardo, Lorenza, et al.
Publicado: (2021)

Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
por: Anstadt, Emily J, et al.
Publicado: (2022)

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
por: Lacouture, Mario E., et al.
Publicado: (2016)

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
por: Kahana, Alon, et al.
Publicado: (2021)

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma
por: Marsh, Katherine M., et al.
Publicado: (2022)

Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta‐analysis of individualized participant data
por: Ørholt, Mathias, et al.
Publicado: (2022)

Synovial sarcomas: A single surgeon experience of 130 cases
por: Andreani, Lorenzo, et al.
Publicado: (2022)

Intralesional margin after excision of a high‐grade osteosarcoma: Is it a catastrophe?
por: Tsagkozis, Panagiotis, et al.
Publicado: (2022)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
por: Thompson, John F., et al.
Publicado: (2014)

Improved Perioperative Seroma and Complication Rates Following the Application of a 2-Layer Negative Pressure Wound Therapy System After Inguinal Lymphadenectomy for Metastatic Cutaneous Melanoma
por: Moncrieff, Marc D., et al.
Publicado: (2020)

Sorting Through the Heterogeneity of Recurrent Melanoma
por: Jacobs, Lisa K., et al.
Publicado: (2008)

Survival and the Sentinel Lymph Node in Melanoma
por: Faries, Mark
Publicado: (2009)

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study
por: Moncrieff, Marc D., et al.
Publicado: (2022)

Cutaneous Melanoma and Sentinel Lymph Node Biopsy
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Isolated Tumor Cells and Long-Term Prognosis of Patients with Melanoma
por: van Akkooi, A. C. J., et al.
Publicado: (2008)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Trends in Sentinel Lymph Node Biopsy Enactment for Cutaneous Melanoma
por: El Sharouni, Mary-Ann, et al.
Publicado: (2019)

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2016)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site
por: Gos, Aleksandra, et al.
Publicado: (2014)

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
por: Wevers, K. P., et al.
Publicado: (2012)

Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients
por: Park, Tristen S., et al.
Publicado: (2017)

COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
por: Davis, Catherine H., et al.
Publicado: (2021)

Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site
por: Prens, Sebastiaan P., et al.
Publicado: (2011)

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients
por: Kruijff, S., et al.
Publicado: (2009)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm)
por: Holmberg, Carl-Jacob, et al.
Publicado: (2023)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1o05sm1nki575oa6haevb4rrvk